UNITED STATES


SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 2054920549

FORM 10-Q

(MARK ONE)

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED: March 31,September 30, 2013

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from ______ to_______

Commission file number 000-51206

 
PLANDAÍ BIOTECHNOLOGY, INC.
(Name of small business issuer in its charter)

 

  
Nevada45-3642179
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
  
2226 Eastlake Avenue East #156, Seattle, WA98102
(Address of principal executive offices)(Zip Code)

 

 
Registrant’s telephone number, including area code: (619)202-7456(435) 881-8734

 

   
Securities registered under Section 12(b) of the Exchange Act: None
   
Securities registered under Section 12(g) of the Exchange Act: Common stock, par value $0.0001 per share
  (Title of Class)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

1

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yesx  No¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yesx No¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

 
Large accelerated filer              ¨¨Accelerated filer                         ¨
Non-accelerated filer                 ¨¨Smaller reporting company   x

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes¨      Nox

 

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:  As of May 10,November 1, 2013, the issuer had 110,645,300106,320,760 shares of its common stock issued and outstanding.

 

 

 

 

2

 

PART 1 – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

 

 

3
 

PLANDAI BIOTECHNOLOGY, INC.

CONSOLIDATED BALANCE SHEETS

        
        
    
  March 31,   June 30,   September 30,   June 30, 
  

2012

(Unaudited)

   

2012

(Audited)

   

2013

(Unaudited)

   

2013

(Audited)

 
ASSETS                
Current Assets:                
Cash $574,760  $5,112  $375,588  $498,917 
Inventory  6,742   —     5,154   6,439 
Accounts Receivable  11,516   —     12,331   13,638 
Related Party Receivable  60,759     
Total Current Assets  593,018   5,112   453,832   518,994 
                
Deposits on Equipment  6,349,488   5,813,990 
Deposits  10,623   10,649 
Other Assets  289,245   22,068   110,919   380,929 
Fixed Assets – Net  1,202,514   215,837   8,315,604   7,924,910 
        
Total Assets $8,434,265  $6,057,007  $8,890,978  $8,835,482 
                
LIABILITIES & STOCKHOLDERS' EQUITY                
Current Liabilities:                
Accounts Payable and Accrued Expenses $388,888  $64,322  $202,116  $516,007 
Accrued Interest  74,276   28,219   115,852   93,184 
Convertible Note Payable  228,500   103,500 
Derivative Liability  273,264   45,227 
Related Party Payables  217,237   7,940   —     145,822 
Total Current Liabilities  680,401   100,481   819,732   903,740 
                
Loans from Related Parties  527,358   402,903   503,269   501,518 
Credit Line  2,208,703   614,168   777,503   752,503 
Capitalized Lease Obligation  1,109,126   988,381 
Long Term Debt, Net of Discount  7,212,182   5,228,990   9,905,711   9,173,702 
TOTAL LIABILITIES  10,628,644   6,346,542   13,115,341   12,319,844 
                
STOCKHOLDERS' DEFICIT                
Common Stock, authorized 500,000,000 shares, $0.0001 par value $.0001, 110,645,300 shares issued and outstanding as of December 3, 2012 and 110,895,300 as of June 30, 2012  11,065   11,090 
Common Stock, authorized 500,000,000 shares, $0.0001 par value $.0001, 106,320,760 and 106,270,760 shares issued and outstanding as of September 30, 2013 and June 30, 2013  10,678   10,628 
Additional Paid-In Capital  7,813,729   7,894,278   7,848,926   7,833,976 
Stock Subscription Payable  261,600   261,600 
Retained Deficit  (9,505,268)  (8,134,698)  (11,474,745)  (10,903,813)
Cumulative Foreign Currency Translation Adjustment  138,061   4,225   167,711   169,437 
Total Stockholders’ Deficit  (1,542,413)  (225,105)  (3,185,830)  (2,628,172)
Non-controlling Interest  (651,966)  (64,430)  (1,038,533)  (856,190)
Equity Allocated to Plandaí Biotechnology  (2,194,379)  (289,535)  (4,224,363)  (3,484,362)
        
Total Liabilities and Stockholders' Deficit $8,434,265  $6,057,007  $8,890,978  $8,835,482 
        
        
The accompanying notes are an integral part of these financial statements.The accompanying notes are an integral part of these financial statements.
The accompanying notes are an integral part of these financial statements.
  
        
        
4

PLANDAI BIOTECHNOLOGY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

PLANDAI BIOTECHNOLOGY, INC.
STATEMENTS OF OPERATIONS
(UNAUDITED)
        
 Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended Three Months Ended
 March 31, March 31, March 31, March 31, September 30, September 30,
 2013 2012 2013 2012 2013 2012
Revenues $65,850  $33,850  $313,716  $49,017   226,953  $133,816 
Cost of Goods  356,363   —     720,838   —   
Cost of Sales  135,397   —   
Gross Profit  (290,513)  33,850   (407,122)  49,017   91,556   133,816 
        
Expenses:                        
Salaries & Wages  115,487   2,172,726   308,523   2,215,450 
Payroll  124,260   115,513 
Professional Services  86,800   180,884 
Rent  189,153   —     216,803   —     178,580   —   
Utilities  2,102   3,276   6,457   20,453   16,730   18,526 
Research  —     —     23,098   —   
Insurance  24,860   —     101,118   —     12,655   —   
Professional Services  114,704   170,075   184,124   170,075 
Depreciation  40,500   —     87,822   —     50,055   14,412 
General & Administrative  180,206   122,194   445,740   150,505   68,827   193,640 
Total Expenses  667,012   2,468,271   1,373,685   2,556,483   537,907   522,975 
        
Operating Income (Loss)  (957,527)  (2,434,421)  (1,780,807)  (2,507,466)  (446,351)  (389,159)
        
Other Income (Expense)        
Derivative Interest  (228,037)  —   
Interest Expense  (73,519)  —     (179,952)  —     (78,886)  (33,576)
Other Income/(Expense)     —     2,653   —   
        
Net Income (Loss) $(1,031,044) $(2,434,421) $(1,958,106) $(2,507,466)  (753,274) $(422,735)
Income (Loss) Allocated to Non-controlling Interest $331,260  $7,507  $587,536  $26,569 
        
Loss Allocated to Non-controlling Interest  182,342   110,665 
        
Net Loss, Adjusted $(699,784) $(2,426,914) $(1,370,570) $(2,480,897)  (570,932) $(312,070)
Other Comprehensive Income (loss):                        
Foreign Currency Translation Adjustment  127,614  (268)  133,836  (268)  (1,726)  410 
Comprehensive Income (Loss) $(572,170) $(2,427,182) $(1,236,735) $(2,481,165)
        
Comprehensive (Loss)  (572,658) $(311,660)
Basic & diluted loss per share $(0.01) $(0.02) $(0.01) $(0.03)  (0.01) $(0.01)
Weighted Avg. Shares Outstanding  110,895,300   104,408,633   110,895,300   87,064,120   106,295,760   110,895,300 
        

 

The accompanying notes are an integral part of these financial statements.

 

5
 

PLANDAI BIOTECHNOLOGY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

     
  For the nine months ended March 31, For the nine months ended March 31,
  2013 2012
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net Loss $(1,370,570) $(2,480,897)
Adjustments to reconcile net loss to net cash        
      provided by operating activities:        
Depreciation  87,822   229 
Loss Allocated to Non-controlling Owners  (587,536)  (26,569)
Stock Issued for Services  (85,000)  2,283,600 
Stock Issued to Retire Third Party Debt  —     69,300 
Foreign Currency Translation Adjustment  133,836   —   
Forgiveness of Interest  4,426   —   
Decrease in Prepaid Expenses  22,068   —   
Increase in Accounts Receivable  (11,516)  —   
Increase in Inventory  (6,742)  —   
Increase in Other Assets  (289,244)  —   
Increase  in Accounts Payable and Accrued Expenses  324,566   15,819 
Increase in Related Party Payables  209,297   —   
Increase in Accrued Interest  46,057   —   
Net Cash Provided by (Used in) Operating Activities  (1,522,536)  (138,458)
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Deposits on Equipment  (535,498)  —   
Repayment of Loans to Related Parties  —     10,265 
Purchase of Fixed Assets  (1,074,499)  (805)
Net Cash Used in Investing Activities  (1,609,997)  9,460 
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Increase in Long-term Debt, Net of Discount  1,983,192   —   
Net Borrowings under Credit Line  1,594,535   —   
Loans from Related Parties  124,454   142,725 
Net Cash Provided by (Used in) Financing Activities  3,702,181   142,725 
         
Net (Decrease) Increase in Cash and Cash Equivalents  569,648   13,727 
Cash and Cash Equivalents at Beginning of Period  5,112   172 
Cash and Cash Equivalents at End of Period $574,760  $13,899 
         
NON-CASH TRANSACTIONS        
Stock issued in share exchange $—    $1,143 
Stock issued for prepaid expenses $—    $582,500 
Stock issued to retire debt $—    $69,300 
SUPPLEMENTAL CASH FLOW INFORMATION:        
Cash paid during the period for:        
Interest $—    $—   
Taxes $—    $—   
         

     
  For the three months ended
September 30,
For the three months ended
September 30,
  2013 2012
         
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net Loss $(753,275) $(422,735)
Adjustments to reconcile net loss to net cash        
      provided by operating activities:        
Depreciation  50,055   14,412 
Forgiveness of Interest  —     2,625 
Derivative Liability  228,037   —   
Capitalized Lease Obligation  120,745   —   
Foreign Currency Translation Adjustment  (1,726)  410 
Increase in Prepaid Expenses  —     (59,690)
Increase in Accounts Receivable  1,307   (28,134)
Decrease in Deposits  25   —   
Decrease in Inventory  1,284   —   
Decrease in Other Assets  270,010   —   
(Decrease) Increase  in Accounts Payable and Accrued Expenses  (313,890)  18,275 
Increase in Related Party Payables  (206,581)  48,468 
Increase in Accrued Interest  22,668   12,133 
Net Cash Used in Operating Activities  (581,339)  (414,236)
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Deposits on Equipment  —     (121,143)
Purchase of Fixed Assets  (440,748)  (606,045)
Net Cash Used in Investing Activities  (440,748)  (727,188)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Increase in Long-term Debt, Net of Discount  732,008   1,319,888 
Net Borrowings under Convertible Debt  125,000   —   
Proceeds from the Sale of Common Stock  15,000   —   
Net Borrowings under Credit Line  25,000   122,175 
Loans from Related Parties  1,750   168,952 
Net Cash Provided by Financing Activities  898,758   1,611,015 
         
Net (Decrease) Increase in Cash and Cash Equivalents  (123,329)  469,591 
Cash and Cash Equivalents at Beginning of Period  498,917   5,112 
Cash and Cash Equivalents at End of Period $375,588  $474,703 
         
SUPPLEMENTAL CASH FLOW INFORMATION:        
Cash paid during the year for:        
Interest $—    $—   
Income taxes $—    $—   
         

The accompanying notes are an integral part of these financial statements.

6
 

 

PLANDAI BIOTECHNOLOGY, INC.

CONSOLIDATED STATEMENTS OF EQUITY

              
   Common Stock   Additional   Foreign   Cummulative         
   Shares   Amount   Paid-in Capital   

Currency

Translation

   Minority Interest   Retained Deficit   Total 
Balance June 30, 2011 (Audited)  76,000,000  $7,600  $4,195,610  $—    $(14,771) $(4,410,050) $(221,611)
Deemed capital contribution from forgiveness of related party debt  —     —     139,458   —     —     —     139,458 
Stock issued on share exchange November 17, 2011  25,415,300   2,542   (2,542)  —     —     —     —   
Foreign currency translation adjustment  —     —     —     4,225   —     —     4,225 
Shares issued as loan origination fee  1,500,000   150   584,850               585,000 
Shares issued for services  7,980,000   798   2,976,902   —     —     —     2,977,700 
Net loss  —     —     —     —     (49,659)  (3,724,648)  (3,774,307)
Balance June 30, 2012 (Audited)  110,895,300   11,090   7,894,278   4,225   (64,430)  (8,134,698)  (289,535)
Cancelled shares  (250,000)  (25)  (84,975)                
Foreign currency translation adjustment  —     —     —     133,836   —     —     (43,044)
Forgiveness of interest  —     —     4,426   —     —     —     4,426 
Net loss  —     —     —     —     (587,536)  (1,370,570)  (1,866,227)
Balance March 31, 2013 (Unaudited)  110,645,300  $11,065  $7,813,729  $138,061  $(651,966) $(9,505,268) $(2,194,379)

The accompanying notes are an integral part of these financial statements.

7

PLANDAI BIOTECHNOLOGY, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINETHREE MONTHS ENDED MARCH 31,SEPTEMBER 30, 2013

(UNAUDITED)

 

NOTE 1 - NATURE OF OPERATIONS AND GOING CONCERN

 

PlandaíBiotechnology, Inc.’s (the “Company” or “Plandaí”) consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustment relating to recoverability and classification of recorded amounts of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company's continued existence is dependent upon its ability to continue to execute its operating plan and to obtain additional debt or equity financing. There can be no assurance the necessary debt or equity financing will be available, or will be available on terms acceptable to the Company.

 

PlandaíBiotechnology, Inc., through its recent acquisition of Global Energy Solutions, Ltd. and its subsidiaries focusesfocus on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the healthnutriceutical and pharmaceutical industries. The company grows much of the live plant material used in its products on a 3,000 hectare estate it operates under a 49-year notarial lease in the Mpumalanga region of South Africa. Plandaí uses a patented extraction process that is designed to yield highly bioavailable products of pharmaceutical-grade purity. The first product to be brought to market is Phytofare™ Catechin Complex, a green-tea derived extract that has multiple potential wellness industry. Itsapplications. The company’s principle holdings consist of land, farms and infrastructure in South Africa.The Company is actively pursuing additional financing and has had discussions with various third parties, although no firm commitments have been obtained. Management believes these efforts will generate sufficient cash flows from future operations to pay the Company's obligations and realize positive cash flow. There is no assurance any of these transactions will occur.

 

These financial statements should be read in conjunction with the Company’s annual report for the year ended June 30, 20122013 previously filed on Form 10-K.In management’s opinion,  all adjustments necessary for a fair statement of the results for the interim periods have been made.  All adjustments  made were of a normal recurring nature.

 

Organization and Basis of Presentation

On November 17, 2011, the Company, through its wholly-owned subsidiary, Plandaí Biotechnologies, Inc., consummated a share exchange with Global Energy Solutions, Inc. (“GES”), an Irish corporation. Under the terms of the share exchange, GES received 76,000,000 shares of the Company’s common stock that had been previously issued to Plandaí in exchange for 100% of the issued and outstanding capital of GES. Concurrent with the share exchange, the Company sold its subsidiary, Diamond Ranch, Ltd., together with its wholly-owned subsidiary, Executive Seafood, Inc., to a former officer and director of Diamond Ranch. Under the terms of the sale, the purchasers assumed all associated debt as consideration. During the three months ended December 31,September 30, 2011 and through the date of the share exchange, Diamond Ranch, Ltd. and Executive Seafood, Inc. had negligible revenues from operations, generated a net loss of $126,000, and as of December 31,September 30, 2011, liabilities exceeded assets by over $5,000,000. The Company subsequently changed its name toPlandaí Biotechnology, Inc. and dissolved GES.

For accounting purposes, the share exchange has been treated as a reverse merger since the acquired entity now forms the basis for operations and the transaction resulted in a change in control, with the acquired company.company electing to become the successor issuer for reporting purposes. The accompanying financial statements have been prepared to reflect the assets, liabilities and operations of Plandaí Biotechnology, Inc. exclusive of Diamond Ranch Foods since the acquisition and sale were executed simultaneously. For equity purposes, the shares issued to acquire GES (76,000,000 shares) have been shown to be issued and outstanding since inception, with the previous balance outstanding (25,415,300 shares Common) treated as a new issuance as of the date of the share exchange. The additional paid-in capital and retained deficit shown are those of GESPlandaí and its subsidiary operations.

In management’s opinion, all adjustments necessary for a fair statement of the results for the presented periods have been made.  All adjustments made were of a normal recurring nature. As a result

7

Basis of Presentation

The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the share exchange, the Company changed its fiscal year end to coincide with thatUnited States of GES, which is June 30.America (“U.S. GAAP”). The accompanying financial statements therefore represent the results of operations for the three and nine months ended March 31,September 30, 2013.

8

NOTE 2 – SUMMARY OF ACCOUNTING POLICIES

This summary of accounting policies for Plandaí Biotechnology, Inc. and its wholly-owned subsidiaries, is presented to assist in understanding the Company's financial statements. The accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the financial statements.

Use of Estimates

The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America. In preparing the financial statements, management is required to make estimates and assumptions that effect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the balance sheet and statement of operations for the year then ended. Actual results may differ from these estimates. Estimates are used when accounting for allowance for bad debts, collect ability of accounts receivable, amounts due to service providers, depreciation and litigation contingencies, among others.

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.

 

Revenue recognition

 

The Company presently derives its revenue from the sale of timber and agricultural products produced on its farm and tea estate holdings in South Africa.The Company follows paragraph 605-10-S99-1 of the FASB Accounting Standards Codification for revenue recognition. The Company will recognize revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured. There are no price incentives and the product can only be returned if defective. As the Company does not believe defective merchandise is likely an allowance has not been recognized. Revenue is recognized on a gross basis with corresponding costswhen the product is delivered to the customer. Once production of goods as a reduction to revenuethe Company’s Phytofare™ botanical extracts commence in cost of sales.2014, revenues will be recognized when product is shipped.

 

Concentration of Credit Risk

 

The Company has no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements.

 

Property and equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization.  The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the related assets, which range from three to five years. Maintenance and repair costs are expensed as they are incurred while renewals and improvements which extend the useful life of an asset are capitalized.  At the time of retirement or disposal of property and equipment, the cost and related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is reflected in the results of operations.

 

Impairment of Long-Lived Assets

 

In accordance with ASC Topic 360, formerly SFAS No. 144,Accounting for the Impairment or Disposal of Long-Lived Assets, the Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be fully recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of its asset based on estimates of its undiscounted future cash flows. If these estimated future cash flows are less than the carrying value of the asset, an impairment charge is recognized for the difference between the asset's estimated fair value and its carrying value. As of the date of these financial statements, the Company is not aware of any items or events that would cause it to adjust the recorded value of its long-lived assets for impairment.

98
 


Earnings per Share

Basic gain or loss per share has been computed by dividing the loss for the period applicable to the common stockholders by the weighted average number of common shares outstanding during the years. At September 30, 2013, the Company had three convertible debentures outstanding that if-converted would result in 786,229 new common shares being issued. At June 30, 2013, the Company had one convertible debenture outstanding that if-converted would result in 340,984 new common shares being issued.

Income Taxes

The Company accounts for income taxes under ASC Topic 740, formerly SFAS No. 109,Accounting for Income Taxes, as clarified by ASC Topic 740, formerly FASB Interpretation No. 48,Accounting for Uncertainty in Income Taxes, (“FIN No. 48”). Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

The Company adopted the provisions of ASC Topic 740, formerly FIN No. 48 on January 1, 2007. Previously, the Company had accounted for tax contingencies in accordance with Statement of Financial Accounting Standards No. 5,Accounting for Contingencies.As required by ASC Topic 450, formerly FIN No. 48, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. At the adoption date, the Company applied ASC Topic 740, formerly FIN No. 48 to all tax positions for which the statute of limitations remained open. As a result of the implementation of ASC Topic 740, formerly FIN No. 48, the Company did not recognize any change in the liability for unrecognized tax benefits.

The Company is subject to income taxes in the U.S. federal jurisdiction and that of South Africa. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for the years before April 1, 2007.

The Company is not currently under examination by any federal or state jurisdiction.

The Company’s policy is to record tax-related interest and penalties as a component of operating expenses.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

 

Emerging Growth Company

We qualify as an “emerging growth company” under the 2012 JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. As an emerging growth company, we can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period.

 

Fair Value of Financial Instruments

 

Fair value of certain of the Company’s financial instruments including cash and cash equivalents, accounts receivable, account payable, accrued expenses, notes payables, and other accrued liabilities approximate cost because of their short maturities. The Company measures and reports fair value in accordance with ASC 820, “Fair Value Measurements and Disclosure” defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value investments.

 

9

Fair value, as defined in ASC 820, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, principal (or most advantageous) markets, and an in-use or an in-exchange valuation premise. The fair value of a liability should reflect the risk of nonperformance, which includes, among other things, the Company’s credit risk.

 

Valuation techniques are generally classified into three categories: the market approach; the income approach; and the cost approach. The selection and application of one or more of the techniques may require significant judgment and are primarily dependent upon the characteristics of the asset or liability, and the quality and availability of inputs. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 also provides fair value hierarchy for inputs and resulting measurement as follows:

 

Level 1

 

Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities; The Company values it’s available for sale securities using Level 1.

 

Level 2

 

Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities; and

 

Level 3

 

Unobservable inputs for the asset or liability that are supported by little or no market activity and that are significant to the fair values.

 

Fair value measurements are required to be disclosed by the Level within the fair value hierarchy in which the fair value measurements in their entirety fall. Fair value measurements using significant unobservable inputs (in Level 3 measurements) are subject to expanded disclosure requirements including a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings, and a description of where those gains or losses included in earning are reported in the statement of income.

 

Advertising

Advertising costs are expensed as incurred.

Principles of Consolidation

PlandaíBiotechnology, Inc. and its subsidiaries, are encompassed in the following entities, which have been consolidated in the accompanying financial statements:

Global Energy Solutions, Ltd. 100% owned by Plandaí Biotechnology, Inc.

Dunn Roman Holdings—Africa, Ltd

Global Energy Solutions, Ltd.100% owned by Plandaí Biotechnology, Inc.
Dunn Roman Holdings—Africa, Ltd82% owned by Plandaí Biotechnology, Inc.
Breakwood Trading 22 (Pty) Ltd.74% owned by Dunn Roman Holdings-Africa
Green Gold Biotechnologies (Pty) Ltd.74% owned by Dunn Roman Holdings-Africa

Breakwood Trading 22 (Pty) Ltd. 74% owned by Dunn Roman Holdings-Africa

Green Gold Biotechnologies (Pty) Ltd. 74% owned by Dunn Roman Holdings-Africa

Subsequent toDuring the year ended June 30, 2012,2013, the Company determined that the entity, Global Energy Solutions, was unnecessary to operations and decided to dissolve that corporation, resulting in the stock of Dunn Roman Holdings-Africa being held directly by Plandaí. All liabilities were either satisfied or forgiven and all bank accounts closed. There were no operations in Global Energy Solutions during the three months ended March 31, 2013. As of March 31, 2013,periods presented. Global Energy Solutions had been dissolved.was officially dissolved during the year ended June 30, 2013.

10

All intercompany balances have been eliminated in consolidation.

Straight-lining of Lease Obligation

Plandaí’s subsidiaries have two long-term, material leases which either have escalating terms or included several months of “free” rent, including the 49-year notarial lease for the Senteeko Tea Estate. In accordance with US Generally Accepted Accounting Principles, the Company has calculated a straight-line monthly cost on the leases and recorded the corresponding difference between the amount actually paid and the amount calculated as a Capitalized Lease Obligation. As of September 30, 2013, the amount of this deferred liability was $1,109,126.


Foreign Currency TranslationRecent Accounting Pronouncements

Recent accounting pronouncements that the Company has adopted or that will be required to adopt in the future are summarized below.

In May 2011, the FASB issued ASC update No. 2011-04,Fair Value Measurement (Topic 820), Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs.  The amendments in this update result in common fair value measurement and disclosure requirements in US generally accepted accounting principles ("U.S. GAAP") and International Financial Reporting Standards ("IFRS").  Consequently, the amendments converge the fair value measurement guidance in U.S. GAAP and IFRS.  Some of the amendments clarify the application of existing fair value measurement requirements, while other amendments change a particular principle in ASC 820. The amendments in this update that change a particular principle or requirement for measuring fair value or disclosing information about fair value measurements include the following:  1) measuring the fair value of financial instruments that are managed within a portfolio, 2) application of premiums and discounts in a fair value measurement, and 3) additional disclosures about fair value measurements.  The amendments in this update are to be applied prospectively and are effective during interim and annual periods beginning after December 15, 2011.  The Company does not believe that adoption of this update will have a material impact on its financial statements.

In June 2011, the FASB issued ASC update No. 2011-05,Comprehensive Income (Topic 220), Presentation of Comprehensive Income.  The FASB decided to eliminate the option to present components of other comprehensive income as part of the statement of changes in stockholders’ equity, among other amendments in this update.  The amendments require that all non-owner changes in stockholder’s equity be presented in a single continuous statement of comprehensive income or in two separate but consecutive statements.  In both choices, the Company is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income.  The statement of other comprehensive income should immediately follow the statement of net income and include the components of other comprehensive income and total for other comprehensive income, along with a total for comprehensive income.  

The entity is also required to present on the face of the financial statements reclassification adjustments for items that are reclassified from other comprehensive income to net income in the statement(s) where the components of net income and the components of comprehensive income are presented.  The amendments in this update should be applied retrospectively, and are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011.

In September 2011, the FASB issued an accounting update that gives companies the option to make a qualitative evaluation about the likelihood of goodwill impairment. Companies will be required to perform the two-step impairment test only if it concludes that the fair value of a reporting unit is more likely than not less than its carrying value. The accounting update is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. We did not early adopt this guidance and do not believe our adoption of the new guidance in 2012 will have a material impact on our consolidated financial position, results of operations or cash flows.

In December 2011, the FASB issued an accounting update that will add new disclosure requirements for entities with recognized financial instruments that are appropriately offset on the balance sheet or that are subject to a master netting arrangement. The accounting update is effective for periods beginning on or after January 1, 2013 with retrospective presentation. We do not believe this guidance will have a material impact on our presentation and disclosure.

11

In December 2010, the FASB (Financial Accounting Standards Board) issued Accounting Standards Update 2010-29 (ASU 2010-29),Business Combinations (Topic 805) – Disclosure of Supplementary Pro Forma Information for Business Combinations. This Accounting Standards Update requires a public entity to disclose pro forma information for business combinations that occurred in the current reporting period. The disclosures include pro forma revenue and earnings of the combined entity for the current reporting period as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. If comparative financial statements are presented, the pro forma revenue and earnings of the combined entity for the comparable prior reporting period should be reported as though the acquisition date for all business combinations that occurred during the current year had been as of the beginning of the comparable prior annual reporting period. The amendments in this Update affect any public entity as defined by Topic 805 that enters into business combinations that are material on an individual or aggregate basis. The amendments in this Update are effective prospectively for business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2010. The adoption of ASU 2010-29 did not have a material effect on its financial position, results of operations or cash flows.

In February 2010, the FASB issued ASU No. 2010-09Subsequent Events (ASC Topic 855) - Amendments to Certain Recognition and Disclosure Requirements (ASU 2010-09). ASU No. 2010-09 requires an entity that is an SEC filer to evaluate subsequent events through the date that the financial statements are issued and removes the requirement for an SEC filer to disclose a date, in both issued and revised financial statements, through which the filer had evaluated subsequent events. The adoption did not have an impact on the Company’s financial position, results of operations or cash flows.

 

Financial Accounting Statement No. 52, Foreign Currency Translation (FAS 52), sets forth the appropriate accounting treatment under U.S. GAAP for companies that consolidate the results of foreign operations denominated in local currencies. FAS 52 requires that all assets and liabilities be translated at the current spot rate at the date of translation. Equity items, other than retained earnings, are translated at the spot rates in effect on each related transaction date. Retained earnings are translated at the weighted-average rate for the relevant year and income statement items are translated at the average rate for the period, except where specific identification is practicable. The resulting adjustment is not recognized in current earnings, but rather as a component of other comprehensive income. The Company adopted FAS 52 in the year ended June 30, 2012 and has chosen US dollars as the local currency. The effect of adopting FAS 52 have been reflected in the accompanying consolidated financial statements.

 

Non-ControllingStatement of Financial Accounting Standards No. 35,Capitalization of Interest Costs, establishes standards for capitalizing interest cost as part of the historical cost of acquiring certain assets. To qualify for interest capitalization, assets must require a period of time to get them ready for their intended use. In the year Ended June 30, 2012, the Company borrowed funds to commence the construction of a manufacturing facility which is expected to be completed during 2013. The company accordingly adopted FAS 35 and capitalized interest associated with the borrowing.

 

Statement of Financial Accounting Standards No. 160,Non-controlling Interests in Consolidated Financial Statements,establishes standards foraccounting for noncontrolling interest, sometimes called a minority interest, which is that portion of equity in a subsidiary not attributable, directly or indirectly, to a parent. FAS 160 requires that the minority portion of equity and net income/loss from operations of consolidated entities be reflected in the financial statements. The Company previously adopted FAS 160 and has reflected the impact in the accompanying consolidated financial statements.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company's present or future financial statements.

NOTE 3 – RECEIVABLE FROM RELATED PARTY

As of September 30, 2013, the Company had advanced $60,759 to a company affiliated to certain of our officers and directors.

 

NOTE 3 – LOANS4 –LOANS FROM RELATED PARTIES

 

12

As of March 31,September 30, 2013, the Company has outstanding loans to various related parties in the amount of $527,358.$503,269. These loans were provided for short-term working capital purposes, bear interest at 4%rates between 8-10%, and become payable once the Company’s obligation to the Land & Agriculture Bank of South Africa has been repaid. Accordingly, this balance has been classified as a long liability as of March 31, 2013. During the nine months ended March 31, 2013, the Company and the note holders agreed forgive $4,426 in interest expense, which was reflected as an increase in Paid In Capital since the note holders were related parties.mature on January 1, 2014.

 

11

NOTE 45 - LINE OF CREDIT

 

During the year ended June 30, 2012, the company entered into a line of credit agreement for $500,000 which was later increased to $1,000,000. The line of credit matures on January 5, 2014 and bears interest at the rate of ten percent (10%) per annum. As of March 31,September 30, 2013, the balance drawn down on the credit line was $752,503$777,503 and accrued interest was $73,337.$115,852. The company is in negotiations to convert the balance outstanding plus accrued interest into common stock and anticipates consummating a resolution to this debt prior to the due date.

NOTE 6 – DEBENTURE PAYABLE

In May 2013, the company issued an 8% interest rate convertible debenture in the amount of $103,500 which becomes due and payable in February 2014. The debenture is convertible into common stock of the company at a discount of 42% off the market price of the company’s common stock six months after issuance (November 2013). The company repaid the debenture in full on November 11, 2013.

On August 20, 2013, the Company executed two convertible promissory notes totaling $550,000. The notes bear interest at the rate of 8% per annum and become due and payable in six months from the date of issuance. During the first 90 days from issuance, the notes are repayable without incurring any interest charges. As of September 30, 2013, the company had been advanced $125,000 against the two notes. When the notes become payable, the holder has the option of converting the unpaid balance of any advances into common stock of the company at a discount of 40% off the then current price per share. Management has made arrangements for these notes to be repaid prior to conversion.

 

The remaining balancecompany has recorded a derivative liability of Line$273,264 representing the estimate value of Credit, $1,456,200, relates to borrowings under the credit facility provided byshares over and above the Land and Agriculture Bankamount of South Africa (see Note 5).debentures that would be issued on conversion.

 

NOTE 57 – LONG-TERM DEBT

 

In June 2012, the Company, through themajority-owned subsidiaries of Dunn Roman Holdings, Inc., executed final loan documents on a 100 million Rand (approx. $13 million USD) financing with the Land and Agriculture Bank of South Africa. The total loan is comprised of multiple agreements totaling, between Green Gold Biotechnologies (Pty) Ltd. and Breakwood Trading 22(Pty) Ltd., 100 million rand. The loans all bear interest at the rate of prime plus 0.5% per annum and are all due in seven years. In addition, the loans have a 25-month “holiday” in which no payments or interest are due until 25 months after the first drawn down of funds. The loans are collateralized by the assets and operations, including the Senteeko lease, agriculture production and receivables of Dunn Roman Holdings, which is the African operating arm of Plandaí. In addition, Dunn Roman Holdings was required to grant a 15% profit share agreement to the Land Bank which extends through the duration of the loan agreements (7 years unless pre-paid). The profit share agreement extends only to profits generated by Dunn Roman Holdings exclusive of operations of Plandaí and outside of South Africa. By wayIn connection with this financing arrangement, the Land and Agriculture Bank of loan covenants,South Africa required the borrowing entities are requiredCompany to maintain athe following loan covenants: debt to equity ratio of 1.5:1, interest coverage ratio of 1.5:1, and security coverage ratio of 1:1. However, the Company is not currently complying with these loan covenants, because the Land and Agriculture Bank of South Africa has temporarily released it from such covenants, until such time that the equipment purchased with the borrowed funds is placed in revenue producing service.

 

As of March 31,September 30, 2013, a total of $7,797,182 has$8,154,904 had been drawn down against the loans by Green Gold Biotechnologies (Pty) Ltd., which was used to purchased fixed assets that will be employed in South Africa to produce the company’s botanical extracts. Additionally, $2,335,806 had been drawn down against the loans by Breakwood Trading22 (Pty) Ltd. to fund the rehabilitation of the Senteeko Tea Estate, including the repair of roads, bridges, and onsite worker housing, and the pruning, weeding and fertilizing of plantation.

13

During the year ended June 30, 2012, the Company issued 1,500,000 shares of restricted common stock to three individuals in exchange for shares of Dunn Roman Holdings stock which had been previously issued. The acquired Dunn Roman shares were then provided to thirds parties in order to comply with the BEE provisions associated with the loan from the Land Bank of South Africa, which required that 15% of Dunn Roman be black owned. The Company has therefore determined to treat the value of the shares issued to acquire the Dunn Roman stock ($585,000) as a cost of securing the financing and recorded as a loan discount which will be amortized over the life of the loan (7 years). once payment of the loan commences in July 2014.

 

As of March 31,September 30, 2013, the loan balance was:

 

Loan Principle $7,797,182

Less: Discount (585,000)

Net Loan per Books$7,212,182

Loan Principle$10,490,711
Less: Discount585,000
Net Loan per Books$9,905,711

 

NOTE 68 – CURRENCY ADJUSTMENT

 

The Company’s principle operations are located in South Africa and the primary currency used is the South African Rand. Accordingly, the financial statements are first prepared in using Rand and then converted to US Dollars for reporting purposes, with the average conversion rate being used for income statement purposes and the closing exchange rate as of March 31,September 30, 2013 applied to the balance sheet. Differences resulting from the fluctuation in the exchange rate are recorded as an offset to equity in the balance sheet. As of March 31,September 30, 2013, the cumulative currency translation adjustments were $138,061.$167,711.

 

12

NOTE 79 – FIXED ASSETS

 

Fixed assets, stated at cost, less accumulated depreciation atMarch 31,September 30, 2013 and June 30, 2012consisted of the following:

 

  

March 31,

2013

 

June 30,

2012

Fixed Assets $        1,284,172 $           215,837
Less: accumulated depreciation (81,658) -
     
  $        1,202,514 $         215,837
     
  September 30,
2013
     
Total Fixed Assets $8,480,680 
Less: Accumulated Depreciation  (165,076)
     
Fixed Assets, net $8,315,604 
     

Depreciation expense

 

Depreciation expense for the ninethree months ended March 31,September 30, 2013 was $87,822. Depreciation expense for the year ended June 30, 2012 was $0. The Company has not begun depreciating the leasehold improvements because they have not been completed as of March 31, 2013. Once completed, the company will begin to amortize over the life of the lease.$50,055.

 

NOTE 810DEPOSIT ON EQUIPMENTCOMMON STOCK

 

Deposit on Equipment consistsDuring the three months ended September 30, 2013, the Company issued a total of machinery and equipment necessary50,000 shares of restricted common stock in exchange for production. A depositproceeds of $6,349,488 has been paid via a loan from Land Bank described in Note 6. Delivery is expected to be completed by the end of August 2013.$15,000.

 

NOTE 911MINORITYNON-CONTROLLING INTEREST

 

Plandaí owns 82% of Dunn Roman Holdings—Africa, which in turn owns 74% each of Breakwood Trading 22 (Pty, Ltd. and Green Gold Biotechnologies (Pty), Ltd., in order to be compliant with the Black Economic Empowerment rules imposed by the South African Land Bank. While the Company, under the Equity Method of Accounting, is required to consolidate 100% of the operations of its majority-owned subsidiaries, that portion of subsidiary net equity attributable to the minority ownership, together with an allocated portion of net income or net loss incurred by the subsidiaries, must be reflected on the consolidated financial statements. On the balance sheet, minority interest has been shown in the Equity Section, separated from the equity of Plandaí, while on the income statement, the minoritynon-controlling shareholder allocation of net loss has been shown in the Consolidated Statement of Operations.

14

NOTE 12 – CAPITALIZED LEASE OBLIGATIONS

In February 2012, the Company entered into a long-term (49 year) lease of tea, avocado, macadamia and timber plantation estates totaling roughly eight thousand acres in South Africa. Under the terms of the lease, the Company is required to pay annual rent of R250,000 ($30,000) plus an annual dividend of 26% of net income generated from the use of the property with a R500,000 ($60,000) annual minimum dividend. The first payment of R20,883 ($2,610) was due April 2012, but by mutual agreement this payment was extended until funding is received under the loan from the Land Bank of South Africa. On March 1, 2012, the Company entered into a 10 year lease for office space for its subsidiary Dunn Roman Holdings. Under the terms of the lease, payments are $2,500 a month.

Both of these leases either have escalating terms or included several months of “free” rent, including the 49-year notarial lease for the Senteeko Tea Estate. In accordance with US Generally Accepted Accounting Principles, the Company has calculated a straight-line monthly cost on the leases and recorded the corresponding difference between the amount actually paid and the amount calculated as a Capitalized Lease Obligation. As of September 30, 2013, the amount of this deferred liability was $1,109,126.

 

NOTE 1013 – RELATED PARTY TRANSACTION

The

In addition to the loans payable and receivables as discussed above, the Company had the following related party transactions during the nine monthsquarter ended March 31, 2013:September 30, 2013.

13

NOTE 11 – SEGMENT INFORMATION

Geographical Locations

The following information summarizes the financial information regarding Plandai Biotechnology Inc. and its three South African Subsidiaries as of and for the nine months ended March 31, 2013:

 South AfricaUnited States
Assets$          8,433,573$                       692
Liabilities            9,620,127               1,008,516
Revenues               313,716                          -
Expenses $         1,167,959 $               375,615

NOTE 12 – COMMON STOCK

The Company is authorized to issue 500,000,000 common shares with a par value of $0.0001.

During the quarter ended March 31,$0.06 per share. At September 30, 2013, the Company cancelled 250,000 shares of common stock that had been issuedaccrued compensation expense for services completed in the prior year for services to be performed. Those services were never rendered, resulting in the shares being returned to the company and cancelled. The valueamount of the shares was previously$261,600, which has been recorded as an $85,000 operating expense. In the three months ended March 31, 2013, the Company recorded an $85,000 reduction in operating expenses.Stock Subscription Payable.

 

NOTE 1314 – SUBSEQUENT EVENTS

 

Management was evaluated subsequent events pursuant to the requirements of ASC Topic 855 and has determined that besides listed below, no material subsequent events exist through the date of this filing.

 

  1. On November 11, 2013, the company paid $143,000 to satisfy its obligation under a convertible debenture issued in May 2013.

 

  1. In November 2013, the company issued a non-convertible promissory note to an unrelated third party in the amount of $250,000. The note is due November 1, 2014 and earns interest at 6% per annum.
1415
 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This statement includes projections of future results and "forward looking statements" as that term is defined in Section 27A of the Securities Act of 1933 as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934 as amended (the "Exchange Act"). All statements that are included in this Quarterly Report, other than statements of historical fact, are forward looking statements. Although management believes that the expectations reflected in these forward looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.

BUSINESS

PlandaíBiotechnology, Inc., (the “Company”) through its recent acquisition of Global Energy Solutions, Ltd. and its subsidiaries, focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principle holdings consist of land, farms and infrastructure in South Africa.

The Company was incorporated, as Jerry's Inc., in the State of Florida on November 30, 1942. The company catered airline flights and operated coffee shops, lounges and gift shops at airports and other facilities located in Florida, Alabama and Georgia. The company's airline catering services included the preparation of meals in kitchens located at, or adjacent to, airports and the distribution of meals and beverages for service on commercial airline flights. The company also provided certain ancillary services, including, among others, the preparation of beverage service carts, the unloading and cleaning of plates, utensils and other accessories arriving on incoming aircraft, and the inventory management and storage of airline-owned dining service equipment. In March of 2004 we moved our domicile to Nevada and changed our name to Diamond Ranch Foods, Ltd. Diamond Ranch Foods, Ltd. was engaged in the meat processing and distribution industry. Operations consisted of packing, processing, custom meat cutting, portion controlled meats, private labeling, and distribution of our products to a diversified customer base, including, but not limited to; in-home food service businesses, retailers, hotels, restaurants and institutions, deli and catering operators, and industry suppliers. On November 17, 2011, the Company, through its wholly-owned subsidiary, Plandaí Biotechnologies, Inc. consummated a share exchange with Global Energy Solutions Corporation Limited, an Irish corporation. Under the terms of the Share Exchange, GES received 76,000,000 shares of Diamond Ranch that had been previously issued to Plandaí Biotechnologies, Inc. in exchange for 100% of the issued and outstanding capital of GES.  On November 21, 2011, the Company filed an amendment to the articles of incorporation to change the name of the company to Plandaí Biotechnology, Inc. 

 

We will continue to seek to raise additional capital through the sale of common stock to fund the expansion of our company. There can be no assurance that we will be successful in raising the capital required and without additional funds we would be unable to expand our plant, acquire other companies, or further implement our business plan. In April 2012, through our subsidiary companies, we secured a 100 million Rand (approximately $13 million) financing with the Land and Agriculture Bank of South Africa which will be used to build infrastructure and further operations.

 

DISPOSITION OF SUBSIDIARY

On November 17, 2011, the Company sold its subsidiary, Diamond Ranch, Ltd., together with its wholly-owned subsidiary, Executive Seafood, Inc. to the former officer and director of Diamond Ranch.  Under the terms of the sale, the purchaser assumed all associated debt as consideration.  During the three and six months prior to their disposition, Diamond Ranch, Ltd. and Executive Seafood, Inc. had negligible revenues from operations, generated a net loss of $126,000, and as of the date of disposition, liabilities exceeded assets by over $5,000,000.

As a result of the Share Exchange Agreement and disposition of Diamond Ranch, Ltd., the operations of Plandaí Biotechnology, Inc. for all periods presented consists exclusively of Plandaí Biotechnologies, Inc,. and its subsidiaries exclusive of Diamond Ranch.

15

PRODUCTS AND SERVICES

 

Plandaí Biotechnologies has a proprietary technology that extracts a high level of bio-available compounds from organic matter including green tea leaves and most other organic materials. Numerous documented scientific studies have been conducted over the past ten years using this technology that releases bioavailable antioxidants and other phytonutrients in form the body can easily absorb. The Company intends to use its notarial leases tofocuses on the farming of whole fruits, vegetables and live plant material and the production of Phytofare™ functional foods and botanical extracts for the health and wellness industry using its proprietary extraction technology.

 

The company is presently developing for market two unique extracts: Phytofare™ Green Tea Catechin Extract and Phytofare™ Citrus Limonoid Glycoside Complex.

16

 

COMPETITION

The Company faces competition from a variety of sources. There are several large producers of farm products including green tea and there are numerous companies that develop and market nutraceutical products that include bio-available compounds including those from green tea extract. Many of these competitors benefit from established distribution, market-ready products, and greater levels of financing. Plandaí intends to compete by producing higher quality and higher concentration extracts, producing at lower costs, and controlling a vertically integrated market that includes all stages from farming through production and marketing.

 

CUSTOMERS

 

Plandaí will market to end users as well as other nutraceutical companies that require high-quality bio-available extracts for their products. In addition, the Company anticipates having surplus farm products including avocado, and macadamia nuts.

SALES

For the three and nine months ended March 31,September 30, 2013, revenues were $65,850 and $313,716, respectively, which$226,953 compared to revenues of $90,785 for the quarter ended September 30, 2012. Sales consisted of sales of avocados, macadamia nuts and timber from the company’s tea estate in South Africa. There was $33,850 and $49,017 inThe company also recorded revenues generated in the three and nine months ended March 31, 2012, respectively, alsoof $196,906 from the sale of avocados, macadamia nuts and timber.  The increase in the current periods resulted from production increases due to proper fertilization, pest control, and prunding, and the expansion of timber production.a license agreement. Sales of Phytofare™ extracts are not expected to commence until FallSummer 2013, when the commercial-grade extraction facility is completedcompleted.

Cost of sales for the quarter ended September 30, 2013 was $135,397, which consists of expenses incurred with managing and restoring the first usable tea leaf is ready for harvest. Senteeko Tea Estate. There were no such costs associated in the prior year as the company had not yet begun rehabilitating the property and therefore no associated farming costs. A third party harvested the fruit and timber and paid the company a fixed price per unit.

 

EXPENSES

 

Our total expenses for the three and nine months ended March 31,September 30, 2013 were $667,012 and  $1,373,685, respectively, which$537,907 compared to $496,146 for the same period of the prior year. Expenses in 2013 consisted primarily of salaries, rent, professional services and general and administrative expenses associatedexpenses. Expenses were comparable from year to year with managing the rehabilitationexception of the tea estate.  For the threerent expense, which did not exist in 2012, and  nine months ended March 31, 2012, expenses were $2,468,271 and $2,556,483,  respectively, which mostly consisted of the recording of stock issued to employees for prior services.  Expenses decreased 73% in the quarter ended March 31, 2013 over 2012 primarily due to a reduction in compensation expense of $2,057,239 resultingprofessional services from the recording of stock for services, which was offset by an increase in rent expense of $189,153.2012 to 2013.

16

 

LIQUIDITY AND CAPITAL RESOURCES

Liquidity is the ability of a company to generate adequate amounts of cash to meet its needs for cash.  The following table provides certain selected balance sheet comparisons between March 31, 2013 and June 30, 2012: 

 March 31,June 30,$%
 20132012ChangeChange
Working Capital         (87,383)             (95,369)      (7,986)(8.3%)
Cash         574,760                 5,112      569,648Over 100%
Total Current Assets         593,018               27,180      565,838Over 100%
Total Assets     8,434,265         6,057,007   2,377,25839.2%
Accounts payable and accrued liabilities         680,401             100,481      579,920Over 100%
Loan from related parties         527,358             402,903      124,45530.9%
Credit Line     2,208,703             614,168   1,594,535259.6%
Long-term debt, net of discount     7,212,182         5,228,990   1,983,19237.9%
Total current liabilities         680,401             100,481      579,920Over 100%
Total liabilities   10,628,644         6,346,542   4,282,10267.5%

At March 31, 2013, our working capital decreased as compared to June 30, 2012 primarily as a result of an increase in current liabilities of $579,920. The increase in current liabilities was due from the increase in accounts payables and accrued expenses which were the result of increased costs incurred for the preparation of operational activity.

Operating Activities

For the ninethree months ended March 31,September 30, 2013, the Company's cash used in operating activities totaled $1,522,536. Non-cash items totaled approximately $151,966$581,340, which included the following:

$87,822 of depreciation
$587,536 of loss allocated to non-controlling owners which represent the minority interest in the Company’s subsidiaries.
$85,000 representing the value of shares issued to consultants for services rendered to the Company 
$133,836 in foreign currency translation adjustment
$4,426 in forgiveness of interest
$22,068 decrease in prepaid expenses
$11,516 increase in accounts receivable
$6,742 increase in inventory which represent the avocadoes, timber, and nuts that are being stored in the warehouse
$289,244 increase in other assets which include deposits and VAT
$324,566 increase in accounts payable and accrued expenses
$209,297 increase in related party payables
$46,057 increase in accrued interest

Investing Activities

Cashwas primarily attributable to a loss from operations, and cash used in investing activities was $1,609,997$440,748, which consisted of $1,074,499the purchase of fixed assets to be used in fixed asset purchases and $535,498 in deposits on equipment.

Financing Activities

production. Cash provided by financing activities was $3,702,181 which consisted of $1,983,192 of advances$898,758, generated by draw downs on the loan from the Land and Agriculture Bank of South Africa $1,594,535and borrowings of draw downs on a line$125,000 under convertible notes. As of credit, and $124,454 in loans from related parties.September 30, 2013, the Company had current assets of $453,832compared to current liabilities of $819,731.

17

PLAN OF OPERATION

The Company's long-term existence is dependent upon our ability to execute our operating plan and to obtain additional debt or equity financing to fund payment of obligations and provide working capital for operations. In April 2012, the Companythrough majority-owned subsidiaries of Dunn Roman Holdings Africa (Pty) Limited , executed final loan documents on a 100 million Rand (approx. $13 million USD) financing with the Land and Agriculture Bank of South Africa and has begun rehabilitating the Senteeko Tea Estate so that it can begin yielding green tea feedstock by Autumnthe end of 2013. The company has also commenced construction of the factory and associated equipment necessary to begin the extraction process on live botanical matter, including green tea and citrus, with a goal to have the factory completed by the end of Spring, 2013. Once the facility is tested and operational, the company will commence processing green tea material for its Phytofare™ Catechin ExtractComplex in Fall 2013, when the first tea is ready for harvest.quarter of 2014.

Management anticipates that it will require additional infusions of capital in order to meet the Company’s long terms and short term operational objectives. Discussions are underway to license aspects of the technology, borrow funds, and secure grants for research and development, a combination of which enable the Company to continue implementing its business plan.

17

CRITICAL ACCOUNTING POLICIES

The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and judgments that affect our reported assets, liabilities, revenues, and expenses, and the disclosure of contingent assets and liabilities. We base our estimates and judgments on historical experience and on various other assumptions we believe to be reasonable under the circumstances. Future events, however, may differ markedly from our current expectations and assumptions. While there are a number of significant accounting policies affecting our financial statements, we believe the following critical accounting policies involve the most complex, difficult and subjective estimates and judgments.

Revenue recognition

The Company derives its revenue from the production and sale of farm goods, raw materials and the sale of bioavailable extracts in both raw material and finished product form.The Company follows paragraph 605-10-S99-1 of the FASB Accounting Standards Codification for Revenues are recognized when product is ordered and delivered. Product shipped on consignment is not counted in revenue recognition. The Company will recognize revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured. The Company mainly sells to retailers. There are no price incentives and the product can only be returned if defective. As the Company does not believe defective merchandise is likely an allowance has not been recognized. Revenue is recognized on a gross basis with corresponding costs of goods as a reduction to revenue in cost of sales.

until sold.

Intangible and Long-Lived Assets

We follow Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 360, “Property Plant and Equipment”, which establishes a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.

Goodwill is accounted for in accordance with ASC Topic 350, “Intangibles – Goodwill and Other”. We assess the impairment of long-lived assets, including goodwill and intangibles on an annual basis or whenever events or changes in circumstances indicate that the fair value is less than its carrying value. Factors that we consider important which could trigger an impairment review include poor economic performance relative to historical or projected future operating results, significant negative industry, economic or company specific trends, changes in the manner of our use of the assets or the plans for our business, market price of our common stock, and loss of key personnel. We have determined that there was no impairment of goodwill during 20112013 or 2010.2012. The share exchange did not result in the recording of goodwill and there is not currently any goodwill recorded.

Potential Derivative Instruments

We periodically assess our financial and equity instruments to determine if they require derivative accounting. Instruments which may potentially require derivative accounting are conversion features of debt and common stock equivalents in excess of available authorized common shares.

Off-Balance Sheet Arrangements


We have no off-balance sheet arrangements.

MinorityNon-Controlling Interest

 

Plandaí owns 82% of Dunn Roman Holdings—Africa, which in turn owns 74% each of Breakwood Trading 22 (Pty, Ltd. and Green Gold Biotechnologies (Pty), Ltd., in order to be compliant with the Black Economic Empowerment rules imposed by the South African Land Bank. While the Company, under the Equity Method of Accounting, is required to consolidate 100% of the operations of its majority-owned subsidiaries, that portion of subsidiary net equity attributable to the minority ownership, together with an allocated portion of net income or net loss incurred by the subsidiaries, must be reflected on the consolidated financial statements. On the balance sheet, minority interest has been shown in the Equity Section, separated from the equity of Plandaí, while on the income statement, the minoritynon-controlling shareholder allocation of net loss has been shown in the Consolidated Statement of Operations.

Currency Translation Adjustment

18

The Company maintains significant operations in South Africa, where the currency is the Rand. The subsidiary financial statements are therefore converted into US dollars prior to consolidation with the parent entity, Plandaí Biotechnology, Inc. US GAAP requires that the weighted average exchange rate be applied to the foreign income statements and that the closing exchange rate as of the period end date be applied to the balance sheet. The cumulative foreign currency adjustment is included in the equity section of the balance sheet.

 

ITEM 3. QUANTITATIVE AND QUALITIVE DISCLOSURES ABOUT MARKET RISK RISKS RELATED TO OUR BUSINESS

 

We Have Historically Lost Money and Losses May Continue in the Future

 

We have historically lost money.   The loss for the fiscal year ended June 30, 20122013 was $3,774,307$2,188,005 and future losses are likely to occur.  Accordingly, we may experience significant liquidity and cash flow problems if we are not able to raise additional capital as needed and on acceptable terms.  No assurances can be given we will be successful in reaching or maintaining profitable operations.

 

We Will Need to Raise Additional Capital to Finance Operations

 

Our operations have relied almost entirely on external financing to fund our operations.  Such financing has historically come from a combination of borrowings and from the sale of common stock and assets to third parties.  We will need to raise additional capital to fund our anticipated operating expenses and future expansion.  Among other things, external financing will be required to cover our operating costs.  We cannot assure you that financing whether from external sources or related parties will be available if needed or on favorable terms.  The sale of our common stock to raise capital may cause dilution to our existing shareholders.  Our inability to obtain adequate financing will result in the need to curtail business operations.  Any of these events would be materially harmful to our business and may result in a lower stock price.

 

19

There is Substantial Doubt About Our Ability to Continue as a Going Concern Due to Recurring Losses and Working Capital Shortages, Which Means that We May Not Be Able to Continue Operations Unless We Obtain Additional Funding

 

The report of our independent accountants on our June 30, 20122013 financial statements include an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern due to recurring losses and working capital shortages.  Our ability to continue as a going concern will be determined by our ability to obtain additional funding.  Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Our Common Stock May Be Affected By Limited Trading Volume and May Fluctuate Significantly

 

There has been a limited public market for our common stock and there can be no assurance that an active trading market for our common stock will develop.  As a result, this could adversely affect our shareholders' ability to sell our common stock in short time periods, or possibly at all.  Our common stock has experienced, and is likely to experience in the future, significant price and volume fluctuations that could adversely affect the market price of our common stock without regard to our operating performance.  In addition, we believe that factors such as quarterly fluctuations in our financial results and changes in the overall economy or the condition of the financial markets could cause the price of our common stock to fluctuate substantially. Substantial fluctuations in our stock price could significantly reduce the price of our stock.

 

19

There is no Assurance of Continued Public Trading Market and Being a Low Priced Security may Affect the Market Value of Our Stock

To date, there has been only a limited public market for our common stock. Our common stock is currently quoted on the OTCBB. As a result, an investor may find it difficult to dispose of, or to obtain accurate quotations as to the market value of our stock. Our stock is subject to the low-priced security or so called "penny stock" rules that impose additional sales practice requirements on broker-dealers who sell such securities. The Securities Enforcement and Penny Stock Reform Act of 1990 requires additional disclosure in connection with any trades involving a stock defined as a penny stock (generally, according to recent regulations adopted by the SEC, any equity security that has a market price of less than $5.00 per share, subject to certain exceptions that we no longer meet). For example, brokers/dealers selling such securities must, prior to effecting the transaction, provide their customers with a document that discloses the risks of investing in such securities. Included in this document are the following:

- the bid and offer price quotes in and for the "penny stock," and the number of shares to which the quoted prices apply,

- the brokerage firm's compensation for the trade, and

- the compensation received by the brokerage firm's sales person for the trade.

 

In addition, the brokerage firm must send the investor:

- a monthly account statement that gives an estimate of the value of each "penny stock" in the investor's account, and

- a written statement of the investor's financial situation and investment goals.

If the person purchasing the securities is someone other than an accredited investor or an established customer of the broker/dealer, the broker/dealer must also approve the potential customer's account by obtaining information concerning the customer's financial situation, investment experience and investment objectives. The broker/dealer must also make a determination whether the transaction is suitable for the customer and whether the customer has sufficient knowledge and experience in financial matters to be reasonably expected to be capable of evaluating the risk of transactions in such securities. Accordingly, the Commission's rules may limit the number of potential purchasers of the shares of our common stock.

 

Resale restrictions on transferring "penny stocks" are sometimes imposed by some states, which may make transaction in our stock more difficult and may reduce the value of the investment. Various state securities laws pose restrictions on transferring "penny stocks" and as a result, investors in our common stock may have the ability to sell their shares of our common stock impaired.

 

20

There can be no assurance we will have market makers in our stock. If the number of market makers in our stock should decline, the liquidity of our common stock could be impaired, not only in the number of shares of common stock which could be bought and sold, but also through possible delays in the timing of transactions, and lower prices for the common stock than might otherwise prevail. Furthermore, the lack of market makers could result in persons being unable to buy or sell shares of the common stock on any secondary market.

 

We Could Fail to Retain or Attract Key Personnel

 

Our future success depends in significant part on the continued services of Roger Duffield, our Chief Executive Officer.President.  We cannot assure you we would be able to find an appropriate replacement for key personnel.  Any loss or interruption of our key personnel's services could adversely affect our ability to develop our business plan.  We have no employment agreements or life insurance on Mr. Duffield.  

 

Nevada Law and Our Charter May Inhibit a Takeover of Our Company That Stockholders May Consider Favorable

 

Provisions of Nevada law, such as its business combination statute, may have the effect of delaying, deferring or preventing a change in control of our company.  As a result, these provisions could limit the price some investors might be willing to pay in the future for shares of our common stock.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “SEC”), and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.

20

 

In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. The design of any system of controls is based, in part, upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, management concluded that our disclosure controls and procedures are effective as of June 30, 20122013 to cause the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods prescribed by SEC, and that such information is accumulated and communicated to management, including our chief executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Changes in Internal Control over Financial Reporting

 

There was no change in our internal controls over financial reporting identified in connection with the requisite evaluation that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

21

PART II  

 

ITEM 1. LEGAL PROCEEDINGS

None.

 

ITEM 1A. RISK FACTORS

This item in not applicable as we are currently considered a smaller reporting company.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None duringDuring the three months ended March 31, 2013.September 30, 2013, the Company sold 50,000 shares of unregistered, restricted common stock for proceeds of $15,000. The shares were issued under an exemption from registration provided by Rule 144 of the Securities Act of 1933.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINING SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

None.

21

ITEM 6. EXHIBITS

 

Plandaí Biotechnology, Inc. includes herewith the following exhibits:

 

   Incorporated by reference
ExhibitExhibit DescriptionFiled herewithFormPeriod endingExhibitFiling date
31.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X    
31.2Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X    
32.1Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X    
32.2Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X    
101.INS*101.INSXBRL Instance DocumentX    
101.SCH*101.SCHXBRL Taxonomy Extension Schema DocumentX    
101.CAL*101.CALXBRL Taxonomy Extension Calculation Linkbase DocumentX    
101.LAB*101.LABXBRL Taxonomy Extension Label Linkbase DocumentX    
101.PRE*101.PREXBRL Taxonomy Extension Presentation Linkbase DocumentX    
101.DEF*101.DEFXBRL Taxonomy Extension Definition Linkbase DefinitionX    

 

 

22
 

 

SIGNATURES

 

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Plandaí Biotechnology, Inc.
(Registrant)

 

Date:  May 20,November 19, 2013

By:/s/ Roger Duffield

Roger Duffield, President

(On behalf of the Registrant and as
Principal Executive Officer)

 


                                       

 

 

 

 

23